18 results on '"Schmid,Johannes M"'
Number of results to display per page
Search Results
2. How to hit the allergy target: A critical appraisal of intralymphatic immunotherapy with practical recommendations on ultrasound‐guided injections
- Author
-
Flory, Stephan, primary, Hviid‐Vyff, Bjarke, additional, Šošić, Lara, additional, Schmid, Johannes M., additional, Ahlbeck, Lars, additional, Widmer, Emma C. J., additional, Lang, Claudia C. V., additional, Ikenberg, Kristian, additional, Kündig, Thomas M., additional, Hoffmann, Hans Jürgen, additional, and Johansen, Pål, additional
- Published
- 2024
- Full Text
- View/download PDF
3. How to hit the allergy target: A critical appraisal of intralymphatic immunotherapy with practical recommendations on ultrasound‐guided injections
- Author
-
Flory, Stephan, Hviid‐Vyff, Bjarke, Šošić, Lara, Schmid, Johannes M, Ahlbeck, Lars; https://orcid.org/0000-0003-1745-6816, Widmer, Emma C J, Lang, Claudia C V, Ikenberg, Kristian, Kündig, Thomas M, Hoffmann, Hans Jürgen; https://orcid.org/0000-0002-6743-7931, Johansen, Pål; https://orcid.org/0000-0002-5055-6299, Flory, Stephan, Hviid‐Vyff, Bjarke, Šošić, Lara, Schmid, Johannes M, Ahlbeck, Lars; https://orcid.org/0000-0003-1745-6816, Widmer, Emma C J, Lang, Claudia C V, Ikenberg, Kristian, Kündig, Thomas M, Hoffmann, Hans Jürgen; https://orcid.org/0000-0002-6743-7931, and Johansen, Pål; https://orcid.org/0000-0002-5055-6299
- Abstract
Background: Intralymphatic immunotherapy (ILIT) represents a promising novel approach treating allergic diseases. However, no standardized procedures or recommendations have been established or reported, despite the recognized fact that treatment efficacy relies on the ability to inject the allergen intranodally. Objective: We aim to provide a critical appraisal of ILIT as a method of allergen immunotherapy and to deliver practical recommendations for accurate ILIT. Methods: One hundred and seventy-three ILIT injections were performed in 28 (47%) women and 32 (53%) men with median age of 29 years (21-59). The injections were ultrasound-guided and recorded for retrospective analysis with respect to injection location, needle visibility, medication release, and patient characteristics. Results: The results show that the correct positioning of the needle within the lymph node (LN) was most critical. If the whole length of the needle bevel was not inserted into the LN, substance backflush into the interstitium was observed. Selecting a more superficial LN and inserting the needle at a smaller angle towards the LN significantly improved needle visibility in the ultrasound. Longitudinal results showed that continuous practice significantly correlated with improved needle visibility and more accurate ILIT injections. Conclusion: Based on our results and practical experience, we propose several recommendations for LN selection and the correct handling of ultrasound probe and needle. We are confident that ILIT standardization and training will be important as to meet the goals of good safety and efficacy of ILIT.
- Published
- 2024
4. EAACI Molecular Allergology User's Guide 2.0
- Author
-
Dramburg, Stephanie, Hilger, Christiane, Santos, Alexandra F., de las Vecillas, Leticia, Aalberse, Rob C., Acevedo, Nathalie, Aglas, Lorenz, Altmann, Friedrich, Arruda, Karla L., Asero, Riccardo, Ballmer-Weber, Barbara, Barber, Domingo, Beyer, Kirsten, Biedermann, Tilo, Bilo, Maria Beatrice, Blank, Simon, Bosshard, Philipp P, Breiteneder, Heimo, Brough, Helen A., Bublin, Merima, Campbell, Dianne, Caraballo, Luis, Caubet, Jean Christoph, Celi, Giorgio, Chapman, Martin D., Chruszcz, Maksymilian, Custovic, Adnan, Czolk, Rebecca, Davies, Janet, Douladiris, Nikolaos, Eberlein, Bernadette, Ebisawa, Motohiro, Ehlers, Anna, Eigenmann, Philippe, Gadermaier, Gabriele, Giovannini, Mattia, Gomez, Francisca, Grohman, Rebecca, Guillet, Carole, Hafner, Christine, Hamilton, Robert G, Hauser, Michael, Hawranek, Thomas, Hoffmann, Hans Jürgen, Holzhauser, Thomas, Iizuka, Tomona, Jacquet, Alain, Jakob, Thilo, Janssen-Weets, Bente, Jappe, Uta, Jutel, Marek, Kalic, Tanja, Kamath, Sandip, Kespohl, Sabine, Kleine-Tebbe, Jörg, Knol, Edward, Knulst, André, Konradsen, Jon R., Korošec, Peter, Kuehn, Annette, Lack, Gideon, Le, Thuy My, Lopata, Andreas, Luengo, Olga, Mäkelä, Mika, Marra, Alessandro Maria, Mills, Clare, Morisset, Martine, Muraro, Antonella, Nowak-Wegrzyn, Anna, Nugraha, Roni, Ollert, Markus, Palosuo, Kati, Pastorello, Elide Anna, Patil, Sarita Ulhas, Platts-Mills, Thomas, Pomés, Anna, Poncet, Pascal, Potapova, Ekaterina, Poulsen, Lars K., Radauer, Christian, Radulovic, Suzana, Raulf, Monika, Rougé, Pierre, Sastre, Joaquin, Sato, Sakura, Scala, Enrico, Schmid, Johannes M., Schmid-Grendelmeier, Peter, Schrama, Denise, Sénéchal, Hélène, Traidl-Hoffmann, Claudia, Valverde-Monge, Marcela, van Hage, Marianne, van Ree, Ronald, Verhoeckx, Kitty, Vieths, Stefan, Wickman, Magnus, Zakzuk, Josefina, Matricardi, Paolo M, Hoffmann-Sommergruber, Karin, Dramburg, Stephanie, Hilger, Christiane, Santos, Alexandra F., de las Vecillas, Leticia, Aalberse, Rob C., Acevedo, Nathalie, Aglas, Lorenz, Altmann, Friedrich, Arruda, Karla L., Asero, Riccardo, Ballmer-Weber, Barbara, Barber, Domingo, Beyer, Kirsten, Biedermann, Tilo, Bilo, Maria Beatrice, Blank, Simon, Bosshard, Philipp P, Breiteneder, Heimo, Brough, Helen A., Bublin, Merima, Campbell, Dianne, Caraballo, Luis, Caubet, Jean Christoph, Celi, Giorgio, Chapman, Martin D., Chruszcz, Maksymilian, Custovic, Adnan, Czolk, Rebecca, Davies, Janet, Douladiris, Nikolaos, Eberlein, Bernadette, Ebisawa, Motohiro, Ehlers, Anna, Eigenmann, Philippe, Gadermaier, Gabriele, Giovannini, Mattia, Gomez, Francisca, Grohman, Rebecca, Guillet, Carole, Hafner, Christine, Hamilton, Robert G, Hauser, Michael, Hawranek, Thomas, Hoffmann, Hans Jürgen, Holzhauser, Thomas, Iizuka, Tomona, Jacquet, Alain, Jakob, Thilo, Janssen-Weets, Bente, Jappe, Uta, Jutel, Marek, Kalic, Tanja, Kamath, Sandip, Kespohl, Sabine, Kleine-Tebbe, Jörg, Knol, Edward, Knulst, André, Konradsen, Jon R., Korošec, Peter, Kuehn, Annette, Lack, Gideon, Le, Thuy My, Lopata, Andreas, Luengo, Olga, Mäkelä, Mika, Marra, Alessandro Maria, Mills, Clare, Morisset, Martine, Muraro, Antonella, Nowak-Wegrzyn, Anna, Nugraha, Roni, Ollert, Markus, Palosuo, Kati, Pastorello, Elide Anna, Patil, Sarita Ulhas, Platts-Mills, Thomas, Pomés, Anna, Poncet, Pascal, Potapova, Ekaterina, Poulsen, Lars K., Radauer, Christian, Radulovic, Suzana, Raulf, Monika, Rougé, Pierre, Sastre, Joaquin, Sato, Sakura, Scala, Enrico, Schmid, Johannes M., Schmid-Grendelmeier, Peter, Schrama, Denise, Sénéchal, Hélène, Traidl-Hoffmann, Claudia, Valverde-Monge, Marcela, van Hage, Marianne, van Ree, Ronald, Verhoeckx, Kitty, Vieths, Stefan, Wickman, Magnus, Zakzuk, Josefina, Matricardi, Paolo M, and Hoffmann-Sommergruber, Karin
- Abstract
Since the discovery of immunoglobulin E (IgE) as a mediator of allergic diseases in 1967, our knowledge about the immunological mechanisms of IgE-mediated allergies has remarkably increased. In addition to understanding the immune response and clinical symptoms, allergy diagnosis and management depend strongly on the precise identification of the elicitors of the IgE-mediated allergic reaction. In the past four decades, innovations in bioscience and technology have facilitated the identification and production of well-defined, highly pure molecules for component-resolved diagnosis (CRD), allowing a personalized diagnosis and management of the allergic disease for individual patients. The first edition of the “EAACI Molecular Allergology User's Guide” (MAUG) in 2016 rapidly became a key reference for clinicians, scientists, and interested readers with a background in allergology, immunology, biology, and medicine. Nevertheless, the field of molecular allergology is moving fast, and after 6 years, a new EAACI Taskforce was established to provide an updated document. The Molecular Allergology User's Guide 2.0 summarizes state-of-the-art information on allergen molecules, their clinical relevance, and their application in diagnostic algorithms for clinical practice. It is designed for both, clinicians and scientists, guiding health care professionals through the overwhelming list of different allergen molecules available for testing. Further, it provides diagnostic algorithms on the clinical relevance of allergenic molecules and gives an overview of their biology, the basic mechanisms of test formats, and the application of tests to measure allergen exposure.
- Published
- 2023
5. EAACI Molecular Allergology User's Guide 2.0
- Author
-
CTI Research, MS Dermatologie/Allergologie, Infection & Immunity, Dramburg, Stephanie, Hilger, Christiane, Santos, Alexandra F, de Las Vecillas, Leticia, Aalberse, Rob C, Acevedo, Nathalie, Aglas, Lorenz, Altmann, Friedrich, Arruda, Karla L, Asero, Riccardo, Ballmer-Weber, Barbara, Barber, Domingo, Beyer, Kirsten, Biedermann, Tilo, Bilo, Maria Beatrice, Blank, Simon, Bosshard, Philipp P, Breiteneder, Heimo, Brough, Helen A, Bublin, Merima, Campbell, Dianne, Caraballo, Luis, Caubet, Jean Christoph, Celi, Giorgio, Chapman, Martin D, Chruszcz, Maksymilian, Custovic, Adnan, Czolk, Rebecca, Davies, Janet, Douladiris, Nikolaos, Eberlein, Bernadette, Ebisawa, Motohiro, Ehlers, Anna, Eigenmann, Philippe, Gadermaier, Gabriele, Giovannini, Mattia, Gomez, Francisca, Grohman, Rebecca, Guillet, Carole, Hafner, Christine, Hamilton, Robert G, Hauser, Michael, Hawranek, Thomas, Hoffmann, Hans Jürgen, Holzhauser, Thomas, Iizuka, Tomona, Jacquet, Alain, Jakob, Thilo, Janssen-Weets, Bente, Jappe, Uta, Jutel, Marek, Kalic, Tanja, Kamath, Sandip, Kespohl, Sabine, Kleine-Tebbe, Jörg, Knol, Edward, Knulst, André, Konradsen, Jon R, Korošec, Peter, Kuehn, Annette, Lack, Gideon, Le, Thuy-My, Lopata, Andreas, Luengo, Olga, Mäkelä, Mika, Marra, Alessandro Maria, Mills, Clare, Morisset, Martine, Muraro, Antonella, Nowak-Wegrzyn, Anna, Nugraha, Roni, Ollert, Markus, Palosuo, Kati, Pastorello, Elide Anna, Patil, Sarita Ulhas, Platts-Mills, Thomas, Pomés, Anna, Poncet, Pascal, Potapova, Ekaterina, Poulsen, Lars K, Radauer, Christian, Radulovic, Suzana, Raulf, Monika, Rougé, Pierre, Sastre, Joaquin, Sato, Sakura, Scala, Enrico, Schmid, Johannes M, Schmid-Grendelmeier, Peter, Schrama, Denise, Sénéchal, Hélène, Traidl-Hoffmann, Claudia, Valverde-Monge, Marcela, van Hage, Marianne, van Ree, Ronald, Verhoeckx, Kitty, Vieths, Stefan, Wickman, Magnus, Zakzuk, Josefina, Matricardi, Paolo M, Hoffmann-Sommergruber, Karin, CTI Research, MS Dermatologie/Allergologie, Infection & Immunity, Dramburg, Stephanie, Hilger, Christiane, Santos, Alexandra F, de Las Vecillas, Leticia, Aalberse, Rob C, Acevedo, Nathalie, Aglas, Lorenz, Altmann, Friedrich, Arruda, Karla L, Asero, Riccardo, Ballmer-Weber, Barbara, Barber, Domingo, Beyer, Kirsten, Biedermann, Tilo, Bilo, Maria Beatrice, Blank, Simon, Bosshard, Philipp P, Breiteneder, Heimo, Brough, Helen A, Bublin, Merima, Campbell, Dianne, Caraballo, Luis, Caubet, Jean Christoph, Celi, Giorgio, Chapman, Martin D, Chruszcz, Maksymilian, Custovic, Adnan, Czolk, Rebecca, Davies, Janet, Douladiris, Nikolaos, Eberlein, Bernadette, Ebisawa, Motohiro, Ehlers, Anna, Eigenmann, Philippe, Gadermaier, Gabriele, Giovannini, Mattia, Gomez, Francisca, Grohman, Rebecca, Guillet, Carole, Hafner, Christine, Hamilton, Robert G, Hauser, Michael, Hawranek, Thomas, Hoffmann, Hans Jürgen, Holzhauser, Thomas, Iizuka, Tomona, Jacquet, Alain, Jakob, Thilo, Janssen-Weets, Bente, Jappe, Uta, Jutel, Marek, Kalic, Tanja, Kamath, Sandip, Kespohl, Sabine, Kleine-Tebbe, Jörg, Knol, Edward, Knulst, André, Konradsen, Jon R, Korošec, Peter, Kuehn, Annette, Lack, Gideon, Le, Thuy-My, Lopata, Andreas, Luengo, Olga, Mäkelä, Mika, Marra, Alessandro Maria, Mills, Clare, Morisset, Martine, Muraro, Antonella, Nowak-Wegrzyn, Anna, Nugraha, Roni, Ollert, Markus, Palosuo, Kati, Pastorello, Elide Anna, Patil, Sarita Ulhas, Platts-Mills, Thomas, Pomés, Anna, Poncet, Pascal, Potapova, Ekaterina, Poulsen, Lars K, Radauer, Christian, Radulovic, Suzana, Raulf, Monika, Rougé, Pierre, Sastre, Joaquin, Sato, Sakura, Scala, Enrico, Schmid, Johannes M, Schmid-Grendelmeier, Peter, Schrama, Denise, Sénéchal, Hélène, Traidl-Hoffmann, Claudia, Valverde-Monge, Marcela, van Hage, Marianne, van Ree, Ronald, Verhoeckx, Kitty, Vieths, Stefan, Wickman, Magnus, Zakzuk, Josefina, Matricardi, Paolo M, and Hoffmann-Sommergruber, Karin
- Published
- 2023
6. EAACI Molecular Allergology User's Guide 2.0
- Author
-
Dramburg, Stephanie, primary, Hilger, Christiane, additional, Santos, Alexandra F., additional, de las Vecillas, Leticia, additional, Aalberse, Rob C., additional, Acevedo, Nathalie, additional, Aglas, Lorenz, additional, Altmann, Friedrich, additional, Arruda, Karla L., additional, Asero, Riccardo, additional, Ballmer‐Weber, Barbara, additional, Barber, Domingo, additional, Beyer, Kirsten, additional, Biedermann, Tilo, additional, Bilo, Maria Beatrice, additional, Blank, Simon, additional, Bosshard, Philipp P., additional, Breiteneder, Heimo, additional, Brough, Helen A., additional, Bublin, Merima, additional, Campbell, Dianne, additional, Caraballo, Luis, additional, Caubet, Jean Christoph, additional, Celi, Giorgio, additional, Chapman, Martin D., additional, Chruszcz, Maksymilian, additional, Custovic, Adnan, additional, Czolk, Rebecca, additional, Davies, Janet, additional, Douladiris, Nikolaos, additional, Eberlein, Bernadette, additional, Ebisawa, Motohiro, additional, Ehlers, Anna, additional, Eigenmann, Philippe, additional, Gadermaier, Gabriele, additional, Giovannini, Mattia, additional, Gomez, Francisca, additional, Grohman, Rebecca, additional, Guillet, Carole, additional, Hafner, Christine, additional, Hamilton, Robert G., additional, Hauser, Michael, additional, Hawranek, Thomas, additional, Hoffmann, Hans Jürgen, additional, Holzhauser, Thomas, additional, Iizuka, Tomona, additional, Jacquet, Alain, additional, Jakob, Thilo, additional, Janssen‐Weets, Bente, additional, Jappe, Uta, additional, Jutel, Marek, additional, Kalic, Tanja, additional, Kamath, Sandip, additional, Kespohl, Sabine, additional, Kleine‐Tebbe, Jörg, additional, Knol, Edward, additional, Knulst, André, additional, Konradsen, Jon R., additional, Korošec, Peter, additional, Kuehn, Annette, additional, Lack, Gideon, additional, Le, Thuy‐My, additional, Lopata, Andreas, additional, Luengo, Olga, additional, Mäkelä, Mika, additional, Marra, Alessandro Maria, additional, Mills, Clare, additional, Morisset, Martine, additional, Muraro, Antonella, additional, Nowak‐Wegrzyn, Anna, additional, Nugraha, Roni, additional, Ollert, Markus, additional, Palosuo, Kati, additional, Pastorello, Elide Anna, additional, Patil, Sarita Ulhas, additional, Platts‐Mills, Thomas, additional, Pomés, Anna, additional, Poncet, Pascal, additional, Potapova, Ekaterina, additional, Poulsen, Lars K., additional, Radauer, Christian, additional, Radulovic, Suzana, additional, Raulf, Monika, additional, Rougé, Pierre, additional, Sastre, Joaquin, additional, Sato, Sakura, additional, Scala, Enrico, additional, Schmid, Johannes M., additional, Schmid‐Grendelmeier, Peter, additional, Schrama, Denise, additional, Sénéchal, Hélène, additional, Traidl‐Hoffmann, Claudia, additional, Valverde‐Monge, Marcela, additional, van Hage, Marianne, additional, van Ree, Ronald, additional, Verhoeckx, Kitty, additional, Vieths, Stefan, additional, Wickman, Magnus, additional, Zakzuk, Josefina, additional, Matricardi, Paolo M., additional, and Hoffmann‐Sommergruber, Karin, additional
- Published
- 2023
- Full Text
- View/download PDF
7. Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study
- Author
-
Menzies-Gow, Andrew N. McBrien, Claire Unni, Bindhu and Porsbjerg, Celeste M. Al-Ahmad, Mona Ambrose, Christopher S. and Assing, Karin Dahl von Bulow, Anna Busby, John Cosio, Borja G. FitzGerald, J. Mark Gil, Esther Garcia Hansen, Susanne and aHeaney, Liam G. Hew, Mark Jackson, David J. Kallieri, Maria Loukides, Stelios Lugogo, Njira L. Papaioannou, I, Andriana Larenas-Linnemann, Desiree Moore, Wendy C. and Perez-de-Llano, Luis A. Rasmussen, Linda M. Schmid, Johannes M. and Siddiqui, Salman Alacqua, Marianna Tran, Trung N. Ulrik, Charlotte Suppli Upham, John W. Wang, Elleen Bulathsinhala, Lakmini Carter, Victoria A. Chaudhry, Isha Eleangovan, Neva and Murray, Ruth B. Price, Chris A. Price, David B. and Menzies-Gow, Andrew N. McBrien, Claire Unni, Bindhu and Porsbjerg, Celeste M. Al-Ahmad, Mona Ambrose, Christopher S. and Assing, Karin Dahl von Bulow, Anna Busby, John Cosio, Borja G. FitzGerald, J. Mark Gil, Esther Garcia Hansen, Susanne and aHeaney, Liam G. Hew, Mark Jackson, David J. Kallieri, Maria Loukides, Stelios Lugogo, Njira L. Papaioannou, I, Andriana Larenas-Linnemann, Desiree Moore, Wendy C. and Perez-de-Llano, Luis A. Rasmussen, Linda M. Schmid, Johannes M. and Siddiqui, Salman Alacqua, Marianna Tran, Trung N. Ulrik, Charlotte Suppli Upham, John W. Wang, Elleen Bulathsinhala, Lakmini Carter, Victoria A. Chaudhry, Isha Eleangovan, Neva and Murray, Ruth B. Price, Chris A. Price, David B.
- Abstract
Introduction: International registries provide opportunities to describe use of biologics for treating severe asthma in current clinical practice. Our aims were to describe real-life global patterns of biologic use (continuation, switches, and discontinuations) for severe asthma, elucidate reasons underlying these patterns, and examine associated patient-level factors. Methods: This was a historical cohort study including adults with severe asthma enrolled into the International Severe Asthma Registry (ISAR; http://isaregistries.org, 2015-2020) or the CHRONICLE Study (2018-2020) and treated with a biologic. Eleven countries were included (Bulgaria, Canada, Denmark, Greece, Italy, Japan, Kuwait, South Korea, Spain, UK, and USA). Biologic utilization patterns were defined: 1) continuing initial biologic; 2) stopping biologic treatment; or 3) switching to another biologic. Reasons for discontinuation/switching were recorded and comparisons drawn between groups. Results: A total of 3531 patients were included. Omalizumab was the most common initial biologic in 2015 (88.2%) and benralizumab in 2019 (29.6%). Most patients (79%; 2791/3531) continued their first biologic; 10.2% (356/3531) stopped; 10.8% (384/3531) switched. The most frequent first switch was from omalizumab to an anti-IL-5/5R (49.6%; 187/377). The most common subsequent switch was from one anti-IL-5/5R to another (44.4%; 20/45). Insufficient efficacy and/or adverse effects were the most frequent reasons for stopping/switching. Patients who stopped/switched were more likely to have a higher baseline blood eosinophil count and exacerbation rate, lower lung function, and greater health care resource utilization. Conclusion: The description of real-life patterns of continuing, stopping, or switching biologics enhances our understanding of global biologic use. Prospective studies involving structured switching criteria could ascertain optimal strategies to identify patients who may benefit from switching.
- Published
- 2022
8. Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study
- Author
-
Menzies-Gow,Andrew N, McBrien,Claire, Unni,Bindhu, Porsbjerg,Celeste M, Al-Ahmad,Mona, Ambrose,Christopher S, Dahl Assing,Karin, von Bülow,Anna, Busby,John, Cosio,Borja G, FitzGerald,J Mark, Garcia Gil,Esther, Hansen,Susanne, Heaney,Liam G, Hew,Mark, Jackson,David J, Kallieri,Maria, Loukides,Stelios, Lugogo,Njira L, Papaioannou,Andriana I, Larenas-Linnemann,Désirée, Moore,Wendy C, Perez-de-Llano,Luis A, Rasmussen,Linda M, Schmid,Johannes M, Siddiqui,Salman, Alacqua,Marianna, Tran,Trung N, Suppli Ulrik,Charlotte, Upham,John W, Wang,Eileen, Bulathsinhala,Lakmini, Carter,Victoria A, Chaudhry,Isha, Eleangovan,Neva, Murray,Ruth B, Price,Chris A, Price,David B, Menzies-Gow,Andrew N, McBrien,Claire, Unni,Bindhu, Porsbjerg,Celeste M, Al-Ahmad,Mona, Ambrose,Christopher S, Dahl Assing,Karin, von Bülow,Anna, Busby,John, Cosio,Borja G, FitzGerald,J Mark, Garcia Gil,Esther, Hansen,Susanne, Heaney,Liam G, Hew,Mark, Jackson,David J, Kallieri,Maria, Loukides,Stelios, Lugogo,Njira L, Papaioannou,Andriana I, Larenas-Linnemann,Désirée, Moore,Wendy C, Perez-de-Llano,Luis A, Rasmussen,Linda M, Schmid,Johannes M, Siddiqui,Salman, Alacqua,Marianna, Tran,Trung N, Suppli Ulrik,Charlotte, Upham,John W, Wang,Eileen, Bulathsinhala,Lakmini, Carter,Victoria A, Chaudhry,Isha, Eleangovan,Neva, Murray,Ruth B, Price,Chris A, and Price,David B
- Abstract
Andrew N Menzies-Gow,1 Claire McBrien,2 Bindhu Unni,3 Celeste M Porsbjerg,4 Mona Al-Ahmad,5 Christopher S Ambrose,6 Karin Dahl Assing,7 Anna von Bülow,4 John Busby,8 Borja G Cosio,9 J Mark FitzGerald,10 Esther Garcia Gil,11 Susanne Hansen,12 Liam G aHeaney,8 Mark Hew,13,14 David J Jackson,15,16 Maria Kallieri,17 Stelios Loukides,17 Njira L Lugogo,18 Andriana I Papaioannou,17 Désirée Larenas-Linnemann,19 Wendy C Moore,20 Luis A Perez-de-Llano,21 Linda M Rasmussen,22 Johannes M Schmid,23 Salman Siddiqui,24 Marianna Alacqua,25 Trung N Tran,6 Charlotte Suppli Ulrik,26 John W Upham,27 Eileen Wang,28,29 Lakmini Bulathsinhala,3,30 Victoria A Carter,3,30 Isha Chaudhry,3,30 Neva Eleangovan,3,30 Ruth B Murray,3,30 Chris A Price,3,30 David B Price3,30,31 1UK Severe Asthma Network and National Registry, Royal Brompton & Harefield Hospitals, London, UK; 2Kingston Hospital, London, UK; 3Observational and Pragmatic Research Institute, Singapore, Singapore; 4Respiratory Research Unit, Bispebjerg University Hospital, Copenhagen, Denmark; 5Al-Rashed Allergy Center, Ministry of Health, Microbiology Department, Faculty of Medicine, Kuwait University, Kuwait, Kuwait; 6AstraZeneca, Gaithersburg, MD, USA; 7Department of Respiratory Medicine, Aalborg University Hospital, Aalborg, Denmark; 8UK Severe Asthma Network and National Registry, Queenâs University Belfast, Belfast, Northern Ireland; 9Son Espases University Hospital-IdISBa-Ciberes, Mallorca, Spain; 10The Centre for Lung Health, Vancouver Coastal Health Research Institute, UBC, Vancouver, Canada; 11AstraZeneca, Barcelona, Spain; 12Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; 13Allergy, Asthma & Clinical Immunology Service, Alfred Health, Melbourne, Australia; 14Public Health and Preventive Medicine, Monash University, Melbourne, Australia; 15UK Severe Asthma Network andNational Registry, Guyâs and St Thomasâ NHS Trust, London, UK; 16School of Immunology &
- Published
- 2022
9. Real World Biologic Use and Switch Patterns in Severe Asthma:Data from the International Severe Asthma Registry and the US CHRONICLE Study
- Author
-
Menzies-Gow, Andrew N., McBrien, Claire, Unni, Bindhu, Porsbjerg, Celeste M., Al-Ahmad, Mona, Ambrose, Christopher S., Dahl Assing, Karin, von Bülow, Anna, Busby, John, Cosio, Borja G., Fitzgerald, J. Mark, Garcia Gil, Esther, Hansen, Susanne, Aheaney, Liam G., Hew, Mark, Jackson, David J., Kallieri, Maria, Loukides, Stelios, Lugogo, Njira L., Papaioannou, Andriana I., Larenas-Linnemann, Désirée, Moore, Wendy C., Perez-De-llano, Luis A., Rasmussen, Linda M., Schmid, Johannes M., Siddiqui, Salman, Alacqua, Marianna, Tran, Trung N., Suppli Ulrik, Charlotte, Upham, John W., Wang, Eileen, Bulathsinhala, Lakmini, Carter, Victoria A., Chaudhry, Isha, Eleangovan, Neva, Murray, Ruth B., Price, Chris A., Price, David B., Menzies-Gow, Andrew N., McBrien, Claire, Unni, Bindhu, Porsbjerg, Celeste M., Al-Ahmad, Mona, Ambrose, Christopher S., Dahl Assing, Karin, von Bülow, Anna, Busby, John, Cosio, Borja G., Fitzgerald, J. Mark, Garcia Gil, Esther, Hansen, Susanne, Aheaney, Liam G., Hew, Mark, Jackson, David J., Kallieri, Maria, Loukides, Stelios, Lugogo, Njira L., Papaioannou, Andriana I., Larenas-Linnemann, Désirée, Moore, Wendy C., Perez-De-llano, Luis A., Rasmussen, Linda M., Schmid, Johannes M., Siddiqui, Salman, Alacqua, Marianna, Tran, Trung N., Suppli Ulrik, Charlotte, Upham, John W., Wang, Eileen, Bulathsinhala, Lakmini, Carter, Victoria A., Chaudhry, Isha, Eleangovan, Neva, Murray, Ruth B., Price, Chris A., and Price, David B.
- Abstract
Introduction: International registries provide opportunities to describe use of biologics for treating severe asthma in current clinical practice. Our aims were to describe real-life global patterns of biologic use (continuation, switches, and discontinuations) for severe asthma, elucidate reasons underlying these patterns, and examine associated patient-level factors. Methods: This was a historical cohort study including adults with severe asthma enrolled into the International Severe Asthma Registry (ISAR; http://isaregistries.org, 2015–2020) or the CHRONICLE Study (2018–2020) and treated with a biologic. Eleven countries were included (Bulgaria, Canada, Denmark, Greece, Italy, Japan, Kuwait, South Korea, Spain, UK, and USA). Biologic utilization patterns were defined: 1) continuing initial biologic; 2) stopping biologic treatment; or 3) switching to another biologic. Reasons for discontinuation/ switching were recorded and comparisons drawn between groups. Results: A total of 3531 patients were included. Omalizumab was the most common initial biologic in 2015 (88.2%) and benralizumab in 2019 (29.6%). Most patients (79%; 2791/3531) continued their first biologic; 10.2% (356/3531) stopped; 10.8% (384/3531) switched. The most frequent first switch was from omalizumab to an anti–IL-5/5R (49.6%; 187/377). The most common subsequent switch was from one anti–IL-5/5R to another (44.4%; 20/45). Insufficient efficacy and/or adverse effects were the most frequent reasons for stopping/switching. Patients who stopped/switched were more likely to have a higher baseline blood eosinophil count and exacerbation rate, lower lung function, and greater health care resource utilization. Conclusion: The description of real-life patterns of continuing, stopping, or switching biologics enhances our understanding of global biologic use. Prospective studies involving structured switching criteria could ascertain optimal strategies to identify patients who may benefit from switching.
- Published
- 2022
10. Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study
- Author
-
Menzies-Gow, Andrew N, primary, McBrien, Claire, additional, Unni, Bindhu, additional, Porsbjerg, Celeste M, additional, Al-Ahmad, Mona, additional, Ambrose, Christopher S, additional, Dahl Assing, Karin, additional, von Bülow, Anna, additional, Busby, John, additional, Cosio, Borja G, additional, FitzGerald, J Mark, additional, Garcia Gil, Esther, additional, Hansen, Susanne, additional, Heaney, Liam G, additional, Hew, Mark, additional, Jackson, David J, additional, Kallieri, Maria, additional, Loukides, Stelios, additional, Lugogo, Njira L, additional, Papaioannou, Andriana I, additional, Larenas-Linnemann, Désirée, additional, Moore, Wendy C, additional, Perez-de-Llano, Luis A, additional, Rasmussen, Linda M, additional, Schmid, Johannes M, additional, Siddiqui, Salman, additional, Alacqua, Marianna, additional, Tran, Trung N, additional, Suppli Ulrik, Charlotte, additional, Upham, John W, additional, Wang, Eileen, additional, Bulathsinhala, Lakmini, additional, Carter, Victoria A, additional, Chaudhry, Isha, additional, Eleangovan, Neva, additional, Murray, Ruth B, additional, Price, Chris A, additional, and Price, David B, additional
- Published
- 2022
- Full Text
- View/download PDF
11. Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma
- Author
-
Prætorius, Katrine, primary, Henriksen, Daniel P., additional, Schmid, Johannes M., additional, Printzlau, Pernille, additional, Pedersen, Lars, additional, Madsen, Hanne, additional, Andersson, Ehm A., additional, Madsen, Louise Klokker, additional, and Chawes, Bo L., additional
- Published
- 2021
- Full Text
- View/download PDF
12. Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma
- Author
-
Praetorius, Katrine, Henriksen, Daniel P., Schmid, Johannes M., Printzlau, Pernille, Pedersen, Lars, Madsen, Hanne, Andersson, Ehm A., Madsen, Louise Klokker, Chawes, Bo L., Praetorius, Katrine, Henriksen, Daniel P., Schmid, Johannes M., Printzlau, Pernille, Pedersen, Lars, Madsen, Hanne, Andersson, Ehm A., Madsen, Louise Klokker, and Chawes, Bo L.
- Published
- 2021
13. Basophil sensitivity reflects long‐term clinical outcome of subcutaneous immunotherapy in grass pollen‐allergic patients
- Author
-
Schmid, Johannes M., primary, Würtzen, Peter A., additional, Siddhuraj, Premkumar, additional, Jogdand, Prajakta, additional, Petersen, Claus G., additional, Dahl, Ronald, additional, Erjefält, Jonas S., additional, and Hoffmann, Hans Jürgen, additional
- Published
- 2020
- Full Text
- View/download PDF
14. Intralymphatic Immunotherapy: Update and Unmet Needs
- Author
-
Senti, Gabriela, Freiburghaus, Andreas U, Larenas-Linnemann, Désirée, Hoffmann, Hans Jürgen, Patterson, Amber M, Klimek, Ludger, Di Bona, Danilo, Pfaar, Oliver, Ahlbeck, Lars, Akdis, Mübeccel, Weinfeld, Dan, Contreras-Verduzco, Francisco A, Pedroza-Melendez, Alvaro, Skaarup, Søren H, Lee, Sang Min, Cardell, Lars-Olaf, Schmid, Johannes M, Westin, Ulla, Dollner, Ralph, Kündig, Thomas M, University of Zurich, and Senti, Gabriela
- Subjects
2403 Immunology ,10183 Swiss Institute of Allergy and Asthma Research ,Immunology ,2723 Immunology and Allergy ,10177 Dermatology Clinic ,Immunology and Allergy ,610 Medicine & health ,General Medicine - Published
- 2019
- Full Text
- View/download PDF
15. Basophil sensitivity reflects long‐term clinical outcome of subcutaneous immunotherapy in grass pollen‐allergic patients.
- Author
-
Schmid, Johannes M., Würtzen, Peter A., Siddhuraj, Premkumar, Jogdand, Prajakta, Petersen, Claus G., Dahl, Ronald, Erjefält, Jonas S., and Hoffmann, Hans Jürgen
- Subjects
- *
TREATMENT effectiveness , *ALLERGIC conjunctivitis , *BASOPHILS , *ALLERGIES , *NASAL mucosa , *IMMUNOTHERAPY - Abstract
Background: Allergic rhinoconjunctivitis is a public health problem. Allergen Immunotherapy is an effective and safe treatment, that modifies the natural course of allergic disease and induces long‐term tolerance. Objective: To correlate basophil and antibody biomarkers of subcutaneous immunotherapy to clinical outcomes and cellular changes in target tissue. Methods: Adults suffering from allergic rhinoconjunctivitis due to grass pollen allergy were randomized to receive subcutaneous immunotherapy (n = 18) or to an open control group (n = 6). Patients reported daily symptom and medication scores and weekly rhinitis related quality of life scores during four pollen seasons. Biomarkers were measured every 3 months for three years treatment and every 6 months in the follow‐up year. Nasal and cutaneous allergen challenge tests were performed annually. Leukocyte subsets were assessed in nasal mucosa biopsies at baseline and after treatment. Results: Subcutaneous immunotherapy led to a 447‐fold decrease in basophil sensitivity during the first treatment year. This remained 100‐fold lower than baseline during the 3 year‐treatment period and 10‐fold lower during the follow‐up year (n = 18, P =.03). Decrease in basophil sensitivity after three weeks of treatment predicted long‐term improvement in seasonal combined symptom and medication scores (ῥ=−0.69, P =.0027) during three years of treatment. AUC of IgE‐blocking factor correlated to nasal allergen challenge (ῥ = 0.63, P =.0012) and SPT (ῥ = 0.45, P =.03). Plasma cell numbers in the nasal mucosa increased during treatment (P =.02). Conclusion: Decrease in basophil sensitivity after three weeks of subcutaneous allergen immunotherapy predicted the clinical outcome of this treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Intralymphatic Immunotherapy: Update and Unmet Needs
- Author
-
Senti, Gabriela, primary, Freiburghaus, Andreas U., additional, Larenas-Linnemann, Désirée, additional, Hoffmann, Hans Jürgen, additional, Patterson, Amber M., additional, Klimek, Ludger, additional, Di Bona, Danilo, additional, Pfaar, Oliver, additional, Ahlbeck, Lars, additional, Akdis, Mübeccel, additional, Weinfeld, Dan, additional, Contreras-Verduzco, Francisco A., additional, Pedroza-Melendez, Alvaro, additional, Skaarup, Søren H., additional, Lee, Sang Min, additional, Cardell, Lars-Olaf, additional, Schmid, Johannes M., additional, Westin, Ulla, additional, Dollner, Ralph, additional, and Kündig, Thomas M., additional
- Published
- 2018
- Full Text
- View/download PDF
17. Grass Pollen Allergic Patients Treated with Subcutaneous Immunotherapy (SCIT) Have Elevated Src-Homology-2 Domain-Containing Inositol-5'phosphatase-1 (SHIP-1) Protein Levels During the Pollen Season
- Author
-
Nasiri, Mohammad, primary, Vonakis, Becky, additional, Schmid, Johannes M., additional, and Hoffmann, Hans Jurgen, additional
- Published
- 2013
- Full Text
- View/download PDF
18. Allergen Specific IgE Titers Are Suppressed by Increased IgG4 Levels When Analyzed by Multiplex Molecular Allergen Chip but Not by Fluoroenzyme Immunoassay
- Author
-
Schmid, Johannes M., Wuertzen, Peter A, Dahl, Ronald, and Hoffmann, Hans Jurgen
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.